Fredrick B. Hagemeister MD

Physician

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161

Dr. Hagemeister is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hagemeister's full profile Already have an account?

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1978 - 1979
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1977 - 1978
Louisiana State University School of MedicineResidency, Internal Medicine, 1973 - 1975
Louisiana State University School of MedicineInternship, Transitional Year, 1972 - 1973
University of Texas Southwestern Medical SchoolClass of 1972

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2027
GA State Medical License 2023 - 2027
LA State Medical License 2023 - 2027
MS State Medical License 2023 - 2027
OK State Medical License 2020 - 2027
TN State Medical License 2023 - 2027
TX State Medical License 1976 - 2027
AL State Medical License 2023 - 2026
WA State Medical License 2023 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015

Clinical Trials

Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
COMPLETED
PHASE3

Publications & Presentations

PubMed

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.
Haopeng Yang, Kotaro Arita, Kevin Bowman, Dai Chihara, Jared Henderson
Blood Cancer Discovery. 2026-09-03
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.
Karan L Chohan, Eduardo Edelman Saul, R Eric Davis, Fredrick Hagemeister, Raphael Steiner
Blood Cancer Journal. 2026-07-02
4 citations
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma.
Neha Akkad, Lei Feng, Jason R Westin, Fredrick B Hagemeister, Hun Ju Lee
Blood Advances. 2025-09-09

Journal Articles

Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin Lymphoma
Peter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology

Abstracts/Posters

Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
F. B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)
Fredrick B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL
F. B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R) in Previously Untreated Follicular...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Current Strategies in the Treatment of Multiple Myeloma, Lymphoma and Leukemia 2012
CancerNet, LLC, Irving, Texas - 5/12/2012